EKF Diagnostics Holdings (LYF) Stock Overview
Engages in the design, development, manufacture, and sale of diagnostic instruments, reagents, and other ancillary products in the Americas, Europe, the Middle East, Asia, Africa, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 0/6 |
| Past Performance | 1/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
LYF Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Join community and earn perks
EKF Diagnostics Holdings plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.27 |
| 52 Week High | UK£0.34 |
| 52 Week Low | UK£0.25 |
| Beta | 0.50 |
| 1 Month Change | -2.14% |
| 3 Month Change | -5.52% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -4.86% |
Recent News & Updates
Recent updates
Shareholder Returns
| LYF | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | -2.1% | -0.3% | -0.005% |
| 1Y | n/a | -17.4% | 3.3% |
Return vs Industry: Insufficient data to determine how LYF performed against the German Medical Equipment industry.
Return vs Market: Insufficient data to determine how LYF performed against the German Market.
Price Volatility
| LYF volatility | |
|---|---|
| LYF Average Weekly Movement | 8.1% |
| Medical Equipment Industry Average Movement | 5.4% |
| Market Average Movement | 5.2% |
| 10% most volatile stocks in DE Market | 12.9% |
| 10% least volatile stocks in DE Market | 2.7% |
Stable Share Price: LYF's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: LYF's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1990 | 301 | Gavin Jones | www.ekfdiagnostics.com |
EKF Diagnostics Holdings plc engages in the design, development, manufacture, and sale of diagnostic instruments, reagents, and other ancillary products in the Americas, Europe, the Middle East, Asia, Africa, and internationally. The company offers DiaSpect Tm analyzer; Hemo Control, a hemoglobin analyzer; and HemataStat II, a microhematocrit centrifuge that provides a quantitative hematocrit reading for six blood samples. It also provides glucose and lactate analyzers, such as Biosen C-Line GP+ and C-Line Clinic; Quo-Lab HbA1c, a desktop point-of-care analyzer for measuring glycated hemoglobin; Quo-Test HbA1c, fully automated hemoglobin A1c analyzer for the monitoring and management of diabetes; and STAT-Site W Beta-Hydroxybutyrate analyzer.
EKF Diagnostics Holdings plc Fundamentals Summary
| LYF fundamental statistics | |
|---|---|
| Market cap | €125.36m |
| Earnings (TTM) | €2.48m |
| Revenue (TTM) | €60.30m |
Is LYF overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LYF income statement (TTM) | |
|---|---|
| Revenue | UK£51.56m |
| Cost of Revenue | UK£25.08m |
| Gross Profit | UK£26.48m |
| Other Expenses | UK£24.36m |
| Earnings | UK£2.12m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
Sep 15, 2026
| Earnings per share (EPS) | 0.0049 |
| Gross Margin | 51.35% |
| Net Profit Margin | 4.12% |
| Debt/Equity Ratio | 0% |
How did LYF perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/08/18 11:45 |
| End of Day Share Price | 2026/08/17 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
EKF Diagnostics Holdings plc is covered by 7 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Julie Simmonds | Canaccord Genuity |
| Jens Lindqvist | Investec Bank plc (UK) |
| Julie Simmonds | Panmure Liberum |